title: A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.
abstract: Deregulated c-Myc occurs in approximately 30% of human cancers. Similarly, hypoxia-inducible factor (HIF) is commonly overexpressed in a variety of human malignancies. Under physiologic conditions, HIF inhibits c-Myc activity; however, when deregulated oncogenic c-Myc collaborates with HIF in inducing the expression of VEGF, PDK1 and hexokinase 2. Most of the knowledge of HIF derives from studies investigating a role of HIF under hypoxic conditions, however, HIF-1alpha stabilization is also found in normoxic conditions. Specifically, under hypoxic conditions HIF-1-mediated regulation of oncogenic c-Myc plays a pivotal role in conferring metabolic advantages to tumor cells as well as adaptation to the tumorigenic micromilieu. In addition, our own results show that under normoxic conditions oncogenic c-Myc is required for constitutive high HIF-1 protein levels and activity in Multiple Myeloma (MM) cells, thereby influencing VEGF secretion and angiogenic activity within the bone marrow microenvironment. Further studies are needed to delineate the functional relevance of HIF, MYC, and the HIF-MYC collaboration in MM and other malignancies, also integrating the tumor microenvironment and the cellular context. Importantly, early studies already demonstrate promising preclinical of novel agents, predominantly small molecules, which target c-Myc, HIF or both.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. klaus_podar@dfci.harvard.edu
authors.forename: Klaus
authors.initials: K
authors.lastname: Podar
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Anderson
mesh_terms: D006593:Hexokinase / Q000378:metabolism; D006801:Humans; D051793:Hypoxia-Inducible Factor 1 / Q000378:metabolism*; D009101:Multiple Myeloma / Q000235:genetics / Q000378:metabolism* / Q000628:therapy; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D016271:Proto-Oncogene Proteins c-myc / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000081382:Pyruvate Dehydrogenase Acetyl-Transferring Kinase; D015398:Signal Transduction; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D051793:Hypoxia-Inducible Factor 1; C000631429:PDK1 protein, human; D016271:Proto-Oncogene Proteins c-myc; D000081382:Pyruvate Dehydrogenase Acetyl-Transferring Kinase; D042461:Vascular Endothelial Growth Factor A; D006593:Hexokinase; D017346:Protein Serine-Threonine Kinases
references.citation: Mol Cell Biol. 1989 Dec;9(12):5395-403
references.pmid: 2685563
references.citation: Nat Rev Cancer. 2003 Oct;3(10):721-32
references.pmid: 13130303
references.citation: Cancer Metastasis Rev. 2007 Jun;26(2):225-39
references.pmid: 17440684
references.citation: Cancer Res. 2000 Aug 1;60(15):4010-5
references.pmid: 10945599
references.citation: Mol Cancer Ther. 2009 Aug;8(8):2329-38
references.pmid: 19671732
references.citation: ChemMedChem. 2007 May;2(5):627-30
references.pmid: 17315254
references.citation: Nat Rev Cancer. 2002 Oct;2(10):764-76
references.pmid: 12360279
references.citation: Sci STKE. 2005 May 17;2005(284):pe23
references.pmid: 15900031
references.citation: EMBO J. 2004 Jul 21;23(14):2830-40
references.pmid: 15241468
references.citation: Nature. 1999 May 20;399(6733):271-5
references.pmid: 10353251
references.citation: Cancer Res. 1997 Dec 1;57(23):5328-35
references.pmid: 9393757
references.citation: Cell Cycle. 2009 May 1;8(9):1359-66
references.pmid: 19377289
references.citation: Blood. 2007 Oct 15;110(8):2996-3004
references.pmid: 17562874
references.citation: Nature. 1991 Sep 26;353(6342):361-3
references.pmid: 1833648
references.citation: Nat Rev Cancer. 2008 Dec;8(12):976-90
references.pmid: 19029958
references.citation: Cancer Res. 2009 Jun 1;69(11):4708-15
references.pmid: 19487287
references.citation: Cancer Res. 2009 Jun 15;69(12):5082-90
references.pmid: 19509231
references.citation: Pancreas. 2007 Mar;34(2):242-7
references.pmid: 17312464
references.citation: J Biol Chem. 2000 Jul 21;275(29):21797-800
references.pmid: 10823814
references.citation: Chem Biol. 2006 Jul;13(7):745-51
references.pmid: 16873022
references.citation: Cell Cycle. 2004 Apr;3(4):456-9
references.pmid: 14963405
references.citation: Int J Cancer. 2008 Nov 15;123(10):2430-7
references.pmid: 18729192
references.citation: Cancer Res. 1999 Nov 15;59(22):5830-5
references.pmid: 10582706
references.citation: Cell. 2006 Aug 25;126(4):663-76
references.pmid: 16904174
references.citation: Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2353-8
references.pmid: 19168635
references.citation: J Natl Cancer Inst. 2003 Apr 2;95(7):516-25
references.pmid: 12671019
references.citation: Cell Cycle. 2006 Oct;5(19):2191-4
references.pmid: 17012843
references.citation: Cancer Cell. 2007 Jan;11(1):37-51
references.pmid: 17222789
references.citation: Mol Cancer Ther. 2006 Jun;5(6):1415-22
references.pmid: 16818499
references.citation: Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17910-5
references.pmid: 19805192
references.citation: Clin Cancer Res. 1998 Nov;4(11):2763-70
references.pmid: 9829740
references.citation: Clin Cancer Res. 2008 Jun 1;14(11):3589-97
references.pmid: 18519793
references.citation: Am J Physiol Lung Cell Mol Physiol. 2002 Apr;282(4):L727-34
references.pmid: 11880298
references.citation: Drug News Perspect. 2007 Dec;20(10):647-54
references.pmid: 18301799
references.citation: Biochem J. 2000 Jun 1;348 Pt 2:257-61
references.pmid: 10816417
references.citation: FEBS J. 2007 Nov;274(21):5533-42
references.pmid: 17916190
references.citation: J Cell Biol. 2007 Jul 2;178(1):93-105
references.pmid: 17606868
references.citation: Nat Rev Cancer. 2008 Jan;8(1):51-6
references.pmid: 18046334
references.citation: Mol Cell Biol. 2008 Jan;28(1):40-9
references.pmid: 17967896
references.citation: Nat Rev Mol Cell Biol. 2004 May;5(5):343-54
references.pmid: 15122348
references.citation: J Biol Chem. 2003 Apr 4;278(14):12563-73
references.pmid: 12529326
references.citation: Cancer Biol Ther. 2005 Nov;4(11):1285-94
references.pmid: 16319523
references.citation: Cancer Res. 2002 Oct 15;62(20):5867-73
references.pmid: 12384550
references.citation: Nature. 1995 Nov 30;378(6556):509-12
references.pmid: 7477410
references.citation: Br J Cancer. 2009 Mar 10;100(5):747-57
references.pmid: 19223896
references.citation: Cancer Cell. 2007 Aug;12(2):108-13
references.pmid: 17692803
references.citation: Cell. 1993 Jan 29;72(2):211-22
references.pmid: 8425218
references.citation: Oncogene. 2007 Jun 7;26(27):3941-51
references.pmid: 17213816
references.citation: BMC Cancer. 2008 Nov 16;8:335
references.pmid: 19014607
references.citation: Haematologica. 2005 Jun;90(6):810-7
references.pmid: 15951294
references.citation: Genome Biol. 2003;4(10):R69
references.pmid: 14519204
references.citation: Biochem J. 2005 Mar 15;386(Pt 3):535-42
references.pmid: 15496140
references.citation: Cancer Cell. 2008 Feb;13(2):167-80
references.pmid: 18242516
references.citation: Mol Cell Biol. 2001 Jun;21(12):3995-4004
references.pmid: 11359907
references.citation: J Clin Invest. 2004 Jun;113(12):1763-73
references.pmid: 15199411
references.citation: Int J Cancer. 2006 Mar 1;118(5):1144-53
references.pmid: 16161047
references.citation: Mol Cell. 2002 May;9(5):1031-44
references.pmid: 12049739
references.citation: Cancer Cell. 2006 Aug;10(2):113-20
references.pmid: 16904610
references.citation: Cancer Res. 2006 Sep 15;66(18):8927-30
references.pmid: 16982728
references.citation: Cell. 2002 May 3;109(3):321-34
references.pmid: 12015982
references.citation: Blood. 2007 Dec 15;110(13):4464-75
references.pmid: 17848618
references.citation: Mol Cell Biol. 1997 Mar;17(3):1459-68
references.pmid: 9032273
references.citation: Crit Rev Oncol Hematol. 2009 May;70(2):93-102
references.pmid: 19186072
references.citation: J Biol Chem. 2006 Nov 17;281(46):34725-9
references.pmid: 16987807
references.citation: Cancer Res. 2006 Jan 15;66(2):770-4
references.pmid: 16424008
references.citation: EMBO J. 2004 May 5;23(9):1949-56
references.pmid: 15071503
references.citation: J Biol Chem. 2004 Feb 13;279(7):5353-62
references.pmid: 14638687
references.citation: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8164-9
references.pmid: 12808131
references.citation: Nat Rev Cancer. 2008 Nov;8(11):865-73
references.pmid: 18923434
references.citation: Science. 1994 Apr 15;264(5157):424-6
references.pmid: 8153630
references.citation: Nat Med. 2004 Jun;10(6):594-601
references.pmid: 15156201
references.citation: J Biol Chem. 2004 Mar 12;279(11):9899-904
references.pmid: 14701857
references.citation: Biochem J. 2008 Jun 15;412(3):477-84
references.pmid: 18393939
references.citation: Mol Cell. 2005 Mar 18;17(6):793-803
references.pmid: 15780936
references.citation: Mol Cell. 2006 Feb 3;21(3):393-404
references.pmid: 16455494
references.citation: Cancer Res. 2006 Mar 15;66(6):3197-204
references.pmid: 16540671
references.citation: Blood. 2008 Mar 15;111(6):3131-6
references.pmid: 18174379
references.citation: Cancer Res. 2005 Oct 1;65(19):9021-8
references.pmid: 16204076
references.citation: Blood. 2007 Sep 15;110(6):2140-7
references.pmid: 17557894
references.citation: Cancer Res. 2007 Apr 1;67(7):2927-31
references.pmid: 17409396
references.citation: J Med Chem. 1998 Sep 24;41(20):3879-87
references.pmid: 9748363
references.citation: Genes Dev. 2002 Oct 1;16(19):2530-43
references.pmid: 12368264
references.citation: Cell Cycle. 2004 Sep;3(9):1133-7
references.pmid: 15467447
references.citation: Cancer Cell. 2007 Sep;12(3):230-8
references.pmid: 17785204
references.citation: Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45
references.pmid: 16064138
references.citation: Nat Rev Cancer. 2008 Feb;8(2):83-93
references.pmid: 18094723
references.citation: Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16768-73
references.pmid: 15556999
references.citation: Radiat Res. 2009 Dec;172(6):653-65
references.pmid: 19929412
references.citation: Br J Cancer. 2007 Jan 15;96(1):95-103
references.pmid: 17179985
references.citation: Mol Cancer Ther. 2008 Nov;7(11):3598-608
references.pmid: 18974394
references.citation: Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):228-33
references.pmid: 10618400
references.citation: Clin Cancer Res. 2009 Dec 1;15(23):7130-6
references.pmid: 19903792
references.citation: Blood. 2007 Nov 15;110(10):3517-25
references.pmid: 17673602
references.citation: Semin Cancer Biol. 2006 Aug;16(4):253-64
references.pmid: 16904903
references.citation: Oncogene. 2005 Jun 23;24(27):4433-41
references.pmid: 15806152
references.citation: Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1551-9
references.pmid: 19028277
references.citation: Genes Dev. 2006 Aug 1;20(15):2096-109
references.pmid: 16847353
references.citation: Nat Rev Cancer. 2004 Jul;4(7):562-8
references.pmid: 15229481
references.citation: Adv Cancer Res. 2002;84:81-154
references.pmid: 11885563
references.citation: Cancer Res. 2007 May 1;67(9):4157-63
references.pmid: 17483326
references.citation: Breast Cancer Res. 2007;9(6):R89
references.pmid: 18096060
references.citation: J Clin Invest. 2009 May;119(5):1093-108
references.pmid: 19363294
references.citation: Mol Cell. 2009 Sep 24;35(6):856-67
references.pmid: 19782034
references.citation: Cancer Cell. 2003 Aug;4(2):133-46
references.pmid: 12957288
references.citation: Cancer Cell. 2007 May;11(5):407-20
references.pmid: 17482131
references.citation: Cell Cycle. 2006 Nov 1;5(21):2430-5
references.pmid: 17102633
references.citation: EMBO J. 1998 Nov 16;17(22):6573-86
references.pmid: 9822602
references.citation: Ann N Y Acad Sci. 2009 Oct;1177:198-204
references.pmid: 19845622
references.citation: Curr Opin Cell Biol. 2007 Apr;19(2):223-9
references.pmid: 17303407
references.citation: Science. 1956 Aug 10;124(3215):269-70
references.pmid: 13351639
references.citation: Cell Death Differ. 2008 Apr;15(4):672-7
references.pmid: 18188166
references.citation: Semin Cancer Biol. 2006 Aug;16(4):288-302
references.pmid: 16938463
references.citation: Mol Cell Biol. 2008 Dec;28(23):7081-95
references.pmid: 18838541
references.citation: Cancer Res. 2005 Oct 1;65(19):9047-55
references.pmid: 16204079
references.citation: Mol Cancer Ther. 2009 Apr;8(4):947-58
references.pmid: 19372568
references.citation: J Biol Chem. 2005 Dec 23;280(51):41928-39
references.pmid: 16223732
references.citation: Genes Dev. 1997 Jan 1;11(1):44-58
references.pmid: 9000049
references.citation: Cancer Res. 2004 Sep 15;64(18):6563-70
references.pmid: 15374969
references.citation: Cancer Res. 2002 Aug 1;62(15):4316-24
references.pmid: 12154035
references.citation: Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6658-63
references.pmid: 9192621
references.citation: Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12095-100
references.pmid: 16103367
references.citation: Cancer Chemother Pharmacol. 2002 Dec;50(6):479-89
references.pmid: 12451475
references.citation: Nature. 2009 Apr 9;458(7239):762-5
references.pmid: 19219026
references.citation: Science. 1998 Sep 4;281(5382):1509-12
references.pmid: 9727977
references.citation: Cell Cycle. 2006 Aug;5(16):1847-53
references.pmid: 16861921
references.citation: Genes Dev. 2003 May 1;17(9):1115-29
references.pmid: 12695333
references.citation: Oncogene. 2005 Jan 27;24(5):889-901
references.pmid: 15580293
references.citation: Blood. 2002 Nov 15;100(10):3767-75
references.pmid: 12393646
references.citation: Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10553-7
references.pmid: 1961720
references.citation: Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6344-9
references.pmid: 16606833
references.citation: Novartis Found Symp. 2006;272:37-49; discussion 49-53, 131-40
references.pmid: 16686428
references.citation: Nature. 1998 Mar 26;392(6674):405-8
references.pmid: 9537326
references.citation: Science. 1956 Feb 24;123(3191):309-14
references.pmid: 13298683
references.citation: Cancer Cell. 2007 Apr;11(4):335-47
references.pmid: 17418410
references.citation: Cancer Cell. 2006 Jun;9(6):425-34
references.pmid: 16766262
references.citation: Nat Rev Cancer. 2009 Jun;9(6):441-4
references.pmid: 19461668